Skip to main content
Fig. 2 | BMC Nephrology

Fig. 2

From: Saccharated ferric oxide attenuates haematopoietic response induced by epoetin beta pegol in patients undergoing haemodialysis

Fig. 2

a. Temporal changes in iFGF23 compared to baseline. Means ± standard deviations of the ratios to baseline are shown. Abbreviations: iFGF23 intact fibroblast growth factor 23, CERA epoetin beta pegol, SFO saccharated ferric oxide, w week. b. Temporal changes in cFGF23 compared to baseline. Means ± standard deviations of the differences from baseline are shown. ††p < 0.01, **p < 0.01 vs. baseline. Abbreviations: cFGF23 C-terminal fibroblast growth factor 23, CERA epoetin beta pegol, SFO saccharated ferric oxide, w week. c. Temporal changes in i/cFGF23 ratio. Means ± standard deviations are shown. †p < 0.05, ††p < 0.01, *p < 0.05 vs. baseline, **p < 0.01 vs. baseline. Abbreviations: i/cFGF23 ratio of intact fibroblast growth factor 23 to C-terminal fibroblast growth factor 23, CERA epoetin beta pegol, SFO saccharated ferric oxide, w week

Back to article page